Aditi Banerjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aditi Banerjee has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Tibor Kristian
Department of Anesthesiology and the Center for Shock, Trauma, and Anesthesiology Research (STAR), University of Maryland School of Medicine, Baltimore, MD 21201, USA
4 shared publications Jaylyn Waddell
Department of Pediatrics, University of Maryland School of Medicine (UMSOM), Baltimore, MD, USA
3 shared publicationsMichal Zalzman
3 shared publicationsNeha Sharda
Department of Pediatrics University of Maryland School of Medicine Baltimore Maryland USA
3 shared publicationsSteven J. Czinn
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA
3 shared publicationsSuprabhat Mukherjee
Integrative Biochemistry & Immunology Laboratory (IBIL), Department of Animal Science, Kazi Nazrul University, Asansol, India
3 shared publications
Latest Publications
- Open Access
- 7 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 31 (45)
Herbal formulas and gastrointestinal motility: Bridging traditional medicine and mechanistic insights
Wang et al provide preclinical evidence that specific traditional herbal formulas, like Pyeongwi-san, can improve gastrointestinal (GI) motility under stress. Pyeongwi-san enhances GI transit, boosts serotonin levels, restores short-chain fatty acid balance, and reduces inflammation. The clinical significance of this research is its potential for standardized herbal remedies for GI disorders, such as dyspepsia and irritable bowel syndrome. At the same time, using only male mice, a single dose regimen, and relatively small cohorts highlights the need for further validation, including sex-specific responses, dose-effect relationships, and translational clinical studies. In summary, readers will find value in this article because it provides mechanistic details, bridges tradition with modern science, deals transparently with its limitations, and paves the way for clinically relevant innovation in GI health. Future investigations should focus on clinical validation and personalized therapeutic strategies that harness both microbiome-gut-brain interactions and the long history of herbal medicine.
- 7 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 31 (45)
Open AccessHerbal formulas and gastrointestinal motility: Bridging traditional medicine and mechanistic insights
Wang et al provide preclinical evidence that specific traditional herbal formulas, like Pyeongwi-san, can improve gastrointestinal (GI) motility under stress. Pyeongwi-san enhances GI transit, boosts serotonin levels, restores short-chain fatty acid balance, and reduces inflammation. The clinical significance of this research is its potential for standardized herbal remedies for GI disorders, such as dyspepsia and irritable bowel syndrome. At the same time, using only male mice, a single dose regimen, and relatively small cohorts highlights the need for further validation, including sex-specific responses, dose-effect relationships, and translational clinical studies. In summary, readers will find value in this article because it provides mechanistic details, bridges tradition with modern science, deals transparently with its limitations, and paves the way for clinically relevant innovation in GI health. Future investigations should focus on clinical validation and personalized therapeutic strategies that harness both microbiome-gut-brain interactions and the long history of herbal medicine.
- 9 August 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 1) , 117221
Targeting the unfolded protein response in cancer: exploiting endoplasmic reticulum stress for therapeutic intervention
- 9 August 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 1) , 117221
Targeting the unfolded protein response in cancer: exploiting endoplasmic reticulum stress for therapeutic intervention
- 23 March 2025
- Published by Elsevier in Cancer Letters
- Vol. 619, 217647
Targeting mitochondrial ribosomal protein expression by andrographolide and melatonin for colon cancer treatment
- 23 March 2025
- Published by Elsevier in Cancer Letters
- Vol. 619, 217647
Targeting mitochondrial ribosomal protein expression by andrographolide and melatonin for colon cancer treatment
- 1 January 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 30 (1) , 31-47
Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics
Background: Medulloblastomas (MDB) are malignant, aggressive brain tumors that primarily affect children. The survival rate for children under 14 is approximately 72%, while for ages 15 to 39, it is around 78%. A growing body of evidence suggests that dysregulation of signaling mechanisms and noncoding RNA epigenetics play a pivotal role in this disease Methodology: This study conducted an electronic search of articles on websites like PubMed and Google. The current review also used an in silico databases search and bioinformatics analysis and an extensive comprehensive literature search for original research articles and review articles as well as retrieval of current and future medications in clinical trials. Results: This study indicates that several signaling pathways, such as sonic hedgehog, WNT/β-catenin, unfolded protein response mediated ER stress, notch, neurotrophins and TGF-β and ERK, MAPK, and ERK play a crucial role in the pathogenesis of MDB. Gene and ncRNA/protein are also involved as an axis long ncRNA to sponge micro-RNAs that affect downstream signal proteins expression and translation affection disease pathophysiology, prognosis and present potential target hit for drug repurposing. Current treatment options include surgery, radiation, and chemotherapy; unfortunately, the disease often relapses, and the survival rate is less than 5%. Therefore, there is a need to develop more effective treatments to combat recurrence and improve survival rates. Conclusion: This review describes various MDB disease hallmarks, including the signaling mechanisms involved in pathophysiology, related-causal genes, epigenetics, downstream genes/epigenes, and possibly the causal disease genes/non-protein coding (nc)RNA/protein axis. Additionally, the challenges associated with MDB treatment are discussed, along with how they are being addressed using nano-technology and nano-biomedicine, with a listing of possible treatment options and future potential treatment modalities.
- 1 January 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 30 (1) , 31-47
Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics
Background: Medulloblastomas (MDB) are malignant, aggressive brain tumors that primarily affect children. The survival rate for children under 14 is approximately 72%, while for ages 15 to 39, it is around 78%. A growing body of evidence suggests that dysregulation of signaling mechanisms and noncoding RNA epigenetics play a pivotal role in this disease Methodology: This study conducted an electronic search of articles on websites like PubMed and Google. The current review also used an in silico databases search and bioinformatics analysis and an extensive comprehensive literature search for original research articles and review articles as well as retrieval of current and future medications in clinical trials. Results: This study indicates that several signaling pathways, such as sonic hedgehog, WNT/β-catenin, unfolded protein response mediated ER stress, notch, neurotrophins and TGF-β and ERK, MAPK, and ERK play a crucial role in the pathogenesis of MDB. Gene and ncRNA/protein are also involved as an axis long ncRNA to sponge micro-RNAs that affect downstream signal proteins expression and translation affection disease pathophysiology, prognosis and present potential target hit for drug repurposing. Current treatment options include surgery, radiation, and chemotherapy; unfortunately, the disease often relapses, and the survival rate is less than 5%. Therefore, there is a need to develop more effective treatments to combat recurrence and improve survival rates. Conclusion: This review describes various MDB disease hallmarks, including the signaling mechanisms involved in pathophysiology, related-causal genes, epigenetics, downstream genes/epigenes, and possibly the causal disease genes/non-protein coding (nc)RNA/protein axis. Additionally, the challenges associated with MDB treatment are discussed, along with how they are being addressed using nano-technology and nano-biomedicine, with a listing of possible treatment options and future potential treatment modalities.
- Open Access
- 11 May 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1192814
Editorial: Women in gastrointestinal cancers, volume II: 2022
Editorial: Women in gastrointestinal cancers, volume II: 2022
- 11 May 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1192814
Open AccessEditorial: Women in gastrointestinal cancers, volume II: 2022
Editorial: Women in gastrointestinal cancers, volume II: 2022
- Open Access
- 12 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 13983
Choline Improves Neonatal Hypoxia-Ischemia Induced Changes in Male but Not Female Rats
Choline is an essential nutrient with many roles in brain development and function. Supplementation of choline in early development can have long-lasting benefits. Our experiments aimed to determine the efficacy of choline supplementation in a postnatal day (PND) 10 rat model of neonatal hypoxia ischemia (HI) at term using both male and female rat pups. Choline (100 mg/kg) or saline administration was initiated the day after birth and given daily for 10 or 14 consecutive days. We determined choline’s effects on neurite outgrowth of sex-specific cultured cerebellar granule cells after HI with and without choline. The magnitude of tissue loss in the cerebrum was determined at 72 h after HI and in adult rats. The efficacy of choline supplementation in improving motor ability and learning, tested using eyeblink conditioning, were assessed in young adult male and female rats. Overall, we find that choline improves neurite outgrowth, short-term histological measures and learning ability in males. Surprisingly, choline did not benefit females, and appears to exacerbate HI-induced changes.
- 12 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 13983
Open AccessCholine Improves Neonatal Hypoxia-Ischemia Induced Changes in Male but Not Female Rats
Choline is an essential nutrient with many roles in brain development and function. Supplementation of choline in early development can have long-lasting benefits. Our experiments aimed to determine the efficacy of choline supplementation in a postnatal day (PND) 10 rat model of neonatal hypoxia ischemia (HI) at term using both male and female rat pups. Choline (100 mg/kg) or saline administration was initiated the day after birth and given daily for 10 or 14 consecutive days. We determined choline’s effects on neurite outgrowth of sex-specific cultured cerebellar granule cells after HI with and without choline. The magnitude of tissue loss in the cerebrum was determined at 72 h after HI and in adult rats. The efficacy of choline supplementation in improving motor ability and learning, tested using eyeblink conditioning, were assessed in young adult male and female rats. Overall, we find that choline improves neurite outgrowth, short-term histological measures and learning ability in males. Surprisingly, choline did not benefit females, and appears to exacerbate HI-induced changes.
- Open Access
- 30 August 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 970491
Editorial: Cancer of gastrointestinal tract: Novel insight into the molecular mechanisms related to inflammation and therapeutic targets
Editorial: Cancer of gastrointestinal tract: Novel insight into the molecular mechanisms related to inflammation and therapeutic targets
- 30 August 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 970491
Open AccessEditorial: Cancer of gastrointestinal tract: Novel insight into the molecular mechanisms related to inflammation and therapeutic targets
Editorial: Cancer of gastrointestinal tract: Novel insight into the molecular mechanisms related to inflammation and therapeutic targets
- 5 June 2022
- Published by Wiley in Journal of Pineal Research
- Vol. 73 (1) , e12808
Melatonin and andrographolide synergize to inhibit the colospheroid phenotype by targeting Wnt/beta‐catenin signaling
β‐catenin signaling, and angiogenesis are associated with colospheroid (CSC), development. CSCs, spheroids derived from colon cancer cells, are responsible for metastasis, drug resistance, and disease recurrence. Whether dysregulating β‐catenin and inhibiting angiogenesis reduce CSC growth is unknown. In this study, the molecular mechanism of CSC growth inhibition was evaluated using a novel combination of melatonin (MLT) and andrographolide (AGP). These drugs have anticarcinogenic, antioxidant, and antimetastatic properties. CSCs were obtained from two metastatic colon cancer cell lines (HT29 and HCT‐15). The viability and stemness were monitored (FDA propidium iodide staining and immunoblot for CD44, CD133, Nanog, Sox2, and Oct4). The drug combination synergistically diminished stemness via increased reactive oxygen species (ROS) levels, reduced mitochondrial membrane potential and ATP level. MLT + AGP induced cell death by inhibiting β‐catenin expression and its downregulatory signals, Cyclin D1, c‐Myc. MLT + AGP treated cells exhibited translocation of phospho‐β‐catenin to the nucleus and dephosphorylated‐β‐catenin. Downregulation of β‐catenin activation and its transcription factors (TCF4 and LEF1) and GTP binding/G‐protein related activity were found in the dual therapy. Angiogenic inhibition is consistent with downregulation of VEGF messenger RNA transcripts (VEGF189), phosphorylated VEGF receptor protein expression, matrigel invasion, and capillary tube inhibition. In vivo, the intravenous injection of MLT + AGP slowed HT29 metastatic colon cancer. Histopathology indicated significant reduction in microvascular density and tumor index. Immunohistochemistry for caspase 7, and β‐catenin found increased apoptosis and downregulation of β‐catenin signals. The mechanism(s) of decreased colospheroids growth were the inhibition of the Wnt/β‐catenin pathway. Our results provide a rationale for using MLT in combination with AGP for the inhibition of CRCs.
- 5 June 2022
- Published by Wiley in Journal of Pineal Research
- Vol. 73 (1) , e12808
Melatonin and andrographolide synergize to inhibit the colospheroid phenotype by targeting Wnt/beta‐catenin signaling
β‐catenin signaling, and angiogenesis are associated with colospheroid (CSC), development. CSCs, spheroids derived from colon cancer cells, are responsible for metastasis, drug resistance, and disease recurrence. Whether dysregulating β‐catenin and inhibiting angiogenesis reduce CSC growth is unknown. In this study, the molecular mechanism of CSC growth inhibition was evaluated using a novel combination of melatonin (MLT) and andrographolide (AGP). These drugs have anticarcinogenic, antioxidant, and antimetastatic properties. CSCs were obtained from two metastatic colon cancer cell lines (HT29 and HCT‐15). The viability and stemness were monitored (FDA propidium iodide staining and immunoblot for CD44, CD133, Nanog, Sox2, and Oct4). The drug combination synergistically diminished stemness via increased reactive oxygen species (ROS) levels, reduced mitochondrial membrane potential and ATP level. MLT + AGP induced cell death by inhibiting β‐catenin expression and its downregulatory signals, Cyclin D1, c‐Myc. MLT + AGP treated cells exhibited translocation of phospho‐β‐catenin to the nucleus and dephosphorylated‐β‐catenin. Downregulation of β‐catenin activation and its transcription factors (TCF4 and LEF1) and GTP binding/G‐protein related activity were found in the dual therapy. Angiogenic inhibition is consistent with downregulation of VEGF messenger RNA transcripts (VEGF189), phosphorylated VEGF receptor protein expression, matrigel invasion, and capillary tube inhibition. In vivo, the intravenous injection of MLT + AGP slowed HT29 metastatic colon cancer. Histopathology indicated significant reduction in microvascular density and tumor index. Immunohistochemistry for caspase 7, and β‐catenin found increased apoptosis and downregulation of β‐catenin signals. The mechanism(s) of decreased colospheroids growth were the inhibition of the Wnt/β‐catenin pathway. Our results provide a rationale for using MLT in combination with AGP for the inhibition of CRCs.
- Open Access
- 2 June 2022
- Published by Wiley in Clinical and Translational Discovery
- Vol. 2 (2)
Commentary on: Pre‐clinical platforms to study therapeutic efficacy of human γδ T cells
This commentary describes chimeric antigen receptors (CAR)‐T cells' impact on solid tumors using novel preclinical models. In haematological malignancies, CAR‐T therapy has had a lot of success. Unfortunately, due to the complex tumour microenvironment (TME) within a solid tumour and the lack of a preclinical model that can recreate this TME complexity, this treatment for solid tumors has failed. Lingling et al., 2022, documented four melanoma organoid models that address many of the significant TME clinical concerns with CAR‐T therapy in solid tumors and observed that γδ T cells treatment in combination with checkpoint inhibitors could significantly improve its infiltration as well as efficacy.
- 2 June 2022
- Published by Wiley in Clinical and Translational Discovery
- Vol. 2 (2)
Open AccessCommentary on: Pre‐clinical platforms to study therapeutic efficacy of human γδ T cells
This commentary describes chimeric antigen receptors (CAR)‐T cells' impact on solid tumors using novel preclinical models. In haematological malignancies, CAR‐T therapy has had a lot of success. Unfortunately, due to the complex tumour microenvironment (TME) within a solid tumour and the lack of a preclinical model that can recreate this TME complexity, this treatment for solid tumors has failed. Lingling et al., 2022, documented four melanoma organoid models that address many of the significant TME clinical concerns with CAR‐T therapy in solid tumors and observed that γδ T cells treatment in combination with checkpoint inhibitors could significantly improve its infiltration as well as efficacy.